Literature DB >> 10656618

Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells.

R Sinha1, S C Kiley, J X Lu, H J Thompson, R Moraes, S Jaken, D Medina.   

Abstract

Methylselenocysteine (MSC), an organic selenium compound is an effective chemopreventive agent against mammary cell growth both in vivo and in vitro but its mechanism of action is still not understood. We have previously demonstrated that MSC is able to inhibit growth in a synchronized TM6 mouse mammary epithelial tumor cell line at 16 h time point followed by apoptosis at 48 h. The decrease in cdk2 kinase activity was coincident with prolonged arrest of cells in S-phase. The present set of experiments showed that cdk2 phosphorylation was reduced by 72% in the MSC-treated cells at 16 h time point. Expression for gadd34, 45 and 153 was elevated 2.5 to 7 fold following MSC treatment only after 16 h time point. In order to investigate a possible upstream target for MSC, we analyzed protein kinase C (PKC) in this model. Total PKC activity was reduced in TM6 cells by MSC (50 microM) within 30 min of treatment, both in cytosolic (55.4 and 77.6%) and membrane (35.2 and 34.1%) fractions for calcium-dependent and independent PKCs, respectively. PMA significantly elevated the PKC activity in membrane fraction (P < 0.01) and MSC inhibited this activation by more than 57%. The effect of MSC was selenium specific as selenomethionine and sulfurmethyl-L-cysteine (SMC) did not alter PKC activity either in cytosolic or membrane fraction. Immunoblot analysis showed that PKC-alpha was translocated to the membrane by PMA and MSC did not alter this translocation. PKC-delta was faintly detectable in membrane fractions of control and MSC-treated cells. MSC treatment slightly reduced levels of PKC-e (in cytosolic and membrane fractions) and PKC-zeta (cytosolic fractions). The data presented herein suggest that PKC is a potential upstream target for MSC that may trigger one or all of the downstream effects; i.e. the decrease of cdk2 kinase activity, decreased DNA synthesis, elevation of gadd gene expression and finally apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10656618     DOI: 10.1016/s0304-3835(99)00250-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Accumulation of an organic anticancer selenium compound in a transgenic Solanaceous species shows wider applicability of the selenocysteine methyltransferase transgene from selenium hyperaccumulators.

Authors:  Marian J McKenzie; Donald A Hunter; Ranjith Pathirana; Lyn M Watson; Nigel I Joyce; Adam J Matich; Daryl D Rowan; David A Brummell
Journal:  Transgenic Res       Date:  2008-12-03       Impact factor: 2.788

2.  ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.

Authors:  Jing-Shan Tong; Qing-Hua Zhang; Zhen-Bo Wang; Sen Li; Cai-Rong Yang; Xue-Qi Fu; Yi Hou; Zhao-Yi Wang; Jun Sheng; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

3.  In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes.

Authors:  Weiqin Jiang; Cheng Jiang; Hongying Pei; Lei Wang; Jinhui Zhang; Hongbo Hu; Junxuan Lü
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

Review 4.  Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Authors:  Junxuan Lü; Jinhui Zhang; Cheng Jiang; Yibin Deng; Nur Özten; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2015-11-23       Impact factor: 2.900

5.  Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

Authors:  Bogdan Prokopczyk; Indu Sinha; Neil Trushin; Willard M Freeman; Karam El-Bayoumy
Journal:  Chem Biol Interact       Date:  2008-11-06       Impact factor: 5.192

6.  Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.

Authors:  Jeong-In Lee; Hui Nian; Arthur J L Cooper; Raghu Sinha; Jenny Dai; William H Bisson; Roderick H Dashwood; John T Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2009-07

7.  Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention.

Authors:  W D Johnson; R L Morrissey; I Kapetanovic; J A Crowell; D L McCormick
Journal:  Food Chem Toxicol       Date:  2007-11-12       Impact factor: 6.023

8.  Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.

Authors:  Hui Nian; William H Bisson; Wan-Mohaiza Dashwood; John T Pinto; Roderick H Dashwood
Journal:  Carcinogenesis       Date:  2009-06-15       Impact factor: 4.944

Review 9.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

10.  Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.

Authors:  Emmanual Unni; Dimpy Koul; Wai-Kwan Alfred Yung; Raghu Sinha
Journal:  Breast Cancer Res       Date:  2005-07-06       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.